Clinical Trials Browser

NETWORK × Carcinoma, Non-Small-Cell Lung × Erlotinib Hydrochloride × Clear all

NCT01068587 2023-08-04

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01562028 2022-08-24

BELIEF

Phase 2 Completed

109 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00436332 2020-04-02

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Phase 2 Completed

84 enrolled 15 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00445848 2020-03-05

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

Phase 2 Completed

89 enrolled 11 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00661193 2020-02-20

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

59 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms